A Chinese delegation led by Vice Premier Liu He could be sent before month's end to iron out phase one, a source tells CNBC's Kayla Tausche.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Online travel company Booking Holdings has dropped out of Facebook's libra, joining a growing list of firms who have exited the embattled cryptocurrency project.Technologyread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Kohl's stores are getting a bit of a refresh, and are being infused with new brands, ahead of this holiday season.Retailread more
Apple will release the iPhone SE2 early next year for $399, analyst Ming-Chi Kuo says.Tech Driversread more
State polls show that Trump's standing has weakened in some states hurt by the trade war.2020 Electionsread more
Sanders, who is recovering from a heart attack, reveals the new tax plan a day before the third Democratic debate.2020 Electionsread more
Investors are set to scrutinize results from Goldman Sachs and J.P. Morgan Chase as banks report third-quarter results starting Tuesday.Financeread more
Morgan Stanley slashed its price target on Netflix to $400 per share from $450 per share, but kept its overweight rating on the stock.Pro Analysisread more
There are at least 10,000 Islamic State prisoners in several camps across northeastern Syria, according to Kurdish and U.S. officials.Politicsread more
Gene therapy stocks are a huge opportunity for growth-oriented investors, according to Goldman Sachs.
The firm is optimistic about this new innovative area of biotechnology, where scientists create disease treatments by editing or replacing human genes.
"We believe investors underappreciate the potential for genome medicine to not only address rare diseases with no existing or limited treatments but also the much larger markets for common diseases," analyst Salveen Richter wrote in a note to clients entitled "The Genome Revolution" Tuesday. "We continue to see upside for the best positioned companies based on the combination of catalysts, rising TAMs [total addressable markets] and M&A potential."
Richter estimates the market size for gene therapies could be as large as $4.8 trillion as "genes are the foundations of all biological activity."
Here are three buy-rated stocks recommended by Goldman Sachs, along with the firm's current price targets.